Literature DB >> 11452239

Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study.

S Härtter1, C Ursing, S Morita, G Tybring, C von Bahr, M Christensen, S Röjdmark, L Bertilsson.   

Abstract

BACKGROUND: Melatonin is a hormone that is metabolized by cytochrome P450 (CYP) 1A2 to its main primary metabolite 6-hydroxymelatonin. We therefore evaluated the utility of oral melatonin as a marker of hepatic CYP1A2 activity.
METHODS: Twenty-five milligrams of melatonin was given at 9:30 am to 12 healthy Swedish volunteers, who had previously been phenotyped for CYP1A2 with caffeine. Melatonin and conjugated 6-hydroxymelatonin were analyzed by liquid chromatography-mass spectrometry in blood samples taken between 0.5 and 6.5 hours after drug intake. Serum concentrations of melatonin and conjugated 6-hydroxymelatonin, or their ratio at different time points, and the apparent melatonin clearance were tested for correlation with caffeine clearance.
RESULTS: We found a significant correlation between apparent clearance of melatonin and caffeine clearance with a Spearman rank correlation coefficient (Rs) of 0.75 (P =.005). The melatonin concentration 1.5 hours after administration also closely correlated with the caffeine clearance (Rs = -0.62; P =.03). Inclusion of conjugated 6-hydroxymelatonin gave no closer correlations.
CONCLUSION: Melatonin might be developed as an alternative to caffeine as a probe drug for CYP1A2 phenotyping.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11452239     DOI: 10.1067/mcp.2001.116512

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  15 in total

1.  Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity.

Authors:  Sebastian Härtter; Anna Nordmark; Dirk-Matthias Rose; Leif Bertilsson; Gunnel Tybring; Kari Laine
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

Review 2.  Phenotyping of Human CYP450 Enzymes by Endobiotics: Current Knowledge and Methodological Approaches.

Authors:  Gaëlle Magliocco; Aurélien Thomas; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

3.  Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans.

Authors:  Roza Ghotbi; Magnus Christensen; Hyung-Keun Roh; Magnus Ingelman-Sundberg; Eleni Aklillu; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2007-03-17       Impact factor: 2.953

4.  Effects of Caffeic Acid and Quercetin on In Vitro Permeability, Metabolism and In Vivo Pharmacokinetics of Melatonin in Rats: Potential for Herb-Drug Interaction.

Authors:  Snehasis Jana; Himanshu Rastogi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

5.  Inhibition of melatonin metabolism in humans induced by chemical components from herbs and effective prediction of this risk using a computational model.

Authors:  Chao Wang; Xiaokui Huo; Xiangge Tian; Min Xu; Peipei Dong; Zhilin Luan; Xiaobo Wang; Baojing Zhang; Bo Zhang; Shanshan Huang; Sa Deng; Xiaochi Ma
Journal:  Br J Pharmacol       Date:  2016-10-10       Impact factor: 8.739

6.  Functional coupling of ATP-binding cassette transporter Abcb6 to cytochrome P450 expression and activity in liver.

Authors:  Hemantkumar Chavan; Feng Li; Robert Tessman; Kristen Mickey; Kenneth Dorko; Timothy Schmitt; Sean Kumer; Sumedha Gunewardena; Nilesh Gaikwad; Partha Krishnamurthy
Journal:  J Biol Chem       Date:  2015-01-26       Impact factor: 5.157

7.  Does hepatic metabolism of melatonin affect the endogenous serum melatonin level in man?

Authors:  C Ursing; S Härtter; C von Bahr; G Tybring; L Bertilsson; S Röjdmark
Journal:  J Endocrinol Invest       Date:  2002-05       Impact factor: 4.256

8.  Influence of cigarette smoking on melatonin levels in man.

Authors:  Carina Ursing; Christer von Bahr; Kerstin Brismar; Sven Röjdmark
Journal:  Eur J Clin Pharmacol       Date:  2005-04-12       Impact factor: 2.953

9.  Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.

Authors:  Trevor N Johnson; Amin Rostami-Hodjegan; Geoffrey T Tucker
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress.

Authors:  Edzard Schwedhelm; Renke Maas; Raphael Troost; Rainer H Böger
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.